Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes smoking cessation aids in the United States and internationally. The company offers Cytisine, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms. It has a license agreement with Sopharma AD and University of Bristol.
Read More…
Industry, Sector and Symbol
Industry Diagnostic substances
Sub-IndustryBiotechnology
SectorMedical
Phone604-210-2217
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$5.06 million
Profitability
Miscellaneous
Employees13
Next Earnings Date11/6/2019 (Estimated)
OptionableNot Optionable
Achieve Life Sciences (NASDAQ:ACHV) Frequently Asked Questions
What is Achieve Life Sciences' stock symbol?
Achieve Life Sciences trades on the NASDAQ under the ticker symbol "ACHV."
When did Achieve Life Sciences' stock split? How did Achieve Life Sciences' stock split work?
Shares of Achieve Life Sciences reverse split on Thursday, May 24th 2018. The 1-10 reverse split was announced on Wednesday, May 23rd 2018. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, May 23rd 2018. An investor that had 100 shares of Achieve Life Sciences stock prior to the reverse split would have 10 shares after the split.
How were Achieve Life Sciences' earnings last quarter?
Achieve Life Sciences Inc (NASDAQ:ACHV) issued its quarterly earnings results on Thursday, August, 8th. The biopharmaceutical company reported ($0.50) EPS for the quarter, missing analysts' consensus estimates of ($0.33) by $0.17. View Achieve Life Sciences' Earnings History.
When is Achieve Life Sciences' next earnings date?
What price target have analysts set for ACHV?
2 analysts have issued 1-year target prices for Achieve Life Sciences' shares. Their predictions range from $6.00 to $20.00. On average, they expect Achieve Life Sciences' stock price to reach $13.00 in the next twelve months. This suggests a possible upside of 778.4% from the stock's current price. View Analyst Price Targets for Achieve Life Sciences.
What is the consensus analysts' recommendation for Achieve Life Sciences?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Achieve Life Sciences in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Achieve Life Sciences.
What are Wall Street analysts saying about Achieve Life Sciences stock?
Here are some recent quotes from research analysts about Achieve Life Sciences stock:
- 1. Maxim Group analysts commented, "Achieve hosted an in NYC with four Key Opinion Leaders (KOLs) of smoking cessation intervention. There are several key takeaways that investors, in our view, should focus on: ○ Need for a new smoking cessation option, particularly on the non- nicotine side. Sure, Glaxo’s (GSK) oral nicotine spray got a positive nod from the Adcom last week and approval is likely. That said, it’s still NRT (nicotine replacement therapy). It has been over a decade since Pfizer’s (PFE – NR) Chantix was approved and it has side effects. ○ Timing in the space, a positive for Achieve- Vaping, deaths and nicotine addiction have captured headlines and continue to shine a light on the need for new therapeutic options. ○ KOLs are on board – At the event, four KOLs, all of whom have extensive experience with NRT and drugs like Chantix appear to be very supportive of the cytisinicline approach." (9/24/2019)
- 2. According to Zacks Investment Research, "Achieve Life Sciences Inc. is a pharmaceutical company. It develops and commercializes cytisine treatment to help people battling nicotine addiction. The Company's product candidates include Custirsen, Apatorsen and OGX-225. Achieve Life Sciences Inc., formerly known as OncoGenex Pharmaceuticals Inc., is based in Bothell, United States. " (1/8/2019)
Has Achieve Life Sciences been receiving favorable news coverage?
Press coverage about ACHV stock has been trending somewhat positive this week, InfoTrie Sentiment reports. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Achieve Life Sciences earned a news impact score of 0.8 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Achieve Life Sciences.
Are investors shorting Achieve Life Sciences?
Achieve Life Sciences saw a decrease in short interest during the month of September. As of September 30th, there was short interest totalling 237,400 shares, a decrease of 29.9% from the August 30th total of 338,700 shares. Based on an average daily trading volume, of 115,600 shares, the short-interest ratio is presently 2.1 days. Approximately 3.1% of the shares of the company are sold short. View Achieve Life Sciences' Current Options Chain.
Who are some of Achieve Life Sciences' key competitors?
Some companies that are related to Achieve Life Sciences include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), Seattle Genetics (SGEN), EXACT Sciences (EXAS), BioMarin Pharmaceutical (BMRN), Array Biopharma (ARRY), Alnylam Pharmaceuticals (ALNY), Neurocrine Biosciences (NBIX) and Ionis Pharmaceuticals (IONS).
What other stocks do shareholders of Achieve Life Sciences own?
Who are Achieve Life Sciences' key executives?
Achieve Life Sciences' management team includes the folowing people:
- Dr. Richard A. B. Stewart, Chairman & CEO (Age 60)
- Dr. Anthony Clarke, Pres, Chief Scientific Officer & Director (Age 63)
- Mr. John A. Bencich, Exec. VP, CFO & COO (Age 42)
- Dr. Cindy Jacobs, Exec. VP & Chief Medical Officer (Age 61)
- Ms. Jaime Xinos, Exec. VP of Commercial
How do I buy shares of Achieve Life Sciences?
Shares of ACHV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Achieve Life Sciences' stock price today?
One share of ACHV stock can currently be purchased for approximately $1.48.
How big of a company is Achieve Life Sciences?
Achieve Life Sciences has a market capitalization of $11.99 million and generates $5.06 million in revenue each year. The biopharmaceutical company earns $-12,690,000.00 in net income (profit) each year or ($3.61) on an earnings per share basis. Achieve Life Sciences employs 13 workers across the globe.View Additional Information About Achieve Life Sciences.
What is Achieve Life Sciences' official website?
How can I contact Achieve Life Sciences?
Achieve Life Sciences' mailing address is 1040 WEST GEORGIA STREET SUITE 1030, VANCOUVER BC, V6E 4H1. The biopharmaceutical company can be reached via phone at 604-210-2217 or via email at [email protected]
MarketBeat Community Rating for Achieve Life Sciences (NASDAQ ACHV)
MarketBeat's community ratings are surveys of what our community members think about Achieve Life Sciences and other stocks. Vote "Outperform" if you believe ACHV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACHV will underperform the S&P 500 over the long term. You may vote once every thirty days.
